Leadership and Board of Directors

Board of Directors

Neal Walker, D.O.

Dr. Walker, the President and Chief Executive Officer of  Aclaris Therapeutics, Inc., joined the Aldeyra board of directors in 2013. He is a board-certified dermatologist and serial entrepreneur with more than 22 years of experience in the biopharmaceutical and life science industries. Prior to founding Aclaris Therapeutics in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.). Dr. Walker has co-founded and led a number of life science companies including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Ltd); Cutix Inc., a commercial dermatology company. He began his pharmaceutical industry career at Johnson and Johnson, Inc. He co-founded and served on the board of directors of the annual Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aclaris Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is also a Fellow of the American Academy of Dermatology. Dr. Walker received his M.B.A. from The Wharton School, University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University.

Gary Phillips, M.D., M.B.A.

Dr. Phillips, the President and Chief Executive Officer of OrphoMed, Inc. since 2018, joined the Aldeyra board of directors in 2009. He served as Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from 2013 to 2018 and held the dual roles of president, U.S. surgical and pharmaceuticals and global head of pharmaceuticals at Bausch & Lomb. He has served as the head of global health at the World Economic Forum in Geneva. Previously, he was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.

Nancy Miller-Rich

Ms. Miller-Rich joined the Aldeyra board of directors in 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Before that she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and previously served as a director of UDG Healthcare plc. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.

Martin J. Joyce, M.B.A.

Mr. Joyce joined the Aldeyra board of directors in 2013. His professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From 2011 to 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from 2006 to 2010. He served as BioSphere’s Chief Financial Officer and Vice President from 2004 to 2006. From 2001 to 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.

Ben Bronstein, M.D.

Dr. Bronstein joined the Aldeyra board of directors in 2010, and is an independent consultant to companies in the life science industry. Prior to his consulting role, he was Executive Vice President, Clinical Development of Aclaris Therapeutics, Inc. Dr. Bronstein has more than 30 years of entrepreneurial and leadership experience across the life science and venture capital industries. He founded or held senior management roles at companies including Neuron Systems, Inc. (the predecessor to Aldeyra Therapeutics, Inc.), BioSurface Technology, Inc., Peptimmune, Inc., OPKO Health, Inc., and Vidus Ocular, Inc. In addition, he was Chief Medical Officer for Stealth BioTherapeutics, Inc., a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School and a founder and Senior Vice President of Access BridgeGap Ventures. A board-certified pathologist with more than 20 publications, Dr. Bronstein began his professional career on the staff of Massachusetts General Hospital and on the faculty of Harvard Medical School. He serves as a board member for several privately held life science companies. Dr. Bronstein received his M.D. and M.B.A. from Boston University.

Richard H. Douglas, Ph.D.

Dr. Douglas joined the Aldeyra board of directors in 2016. He is the former Senior Vice President, Corporate Development of Genzyme Corporation, and since 2011 has been an independent consultant and advisor at Red Sky Partners LLC. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company, and MaxCyte, Inc., a publically traded clinical-stage biopharmaceutical company. He also serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology.

Todd C. Brady, M.D., Ph.D.

Dr. Brady has served as the President and Chief Executive Officer of Aldeyra since 2012 and as a member of our board of directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady serves on the board of directors of Evoke Pharma, Inc. a publicly traded specialty pharmaceutical company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College.